BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10482188)

  • 1. Gene therapy for prostate cancer.
    Hrouda D; Perry M; Dalgleish AG
    Semin Oncol; 1999 Aug; 26(4):455-71. PubMed ID: 10482188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gene therapy for prostate cancer.
    Hrouda D; Dalgleish AG
    Gene Ther; 1996 Oct; 3(10):845-52. PubMed ID: 8908497
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.
    Simons JW; Mikhak B; Chang JF; DeMarzo AM; Carducci MA; Lim M; Weber CE; Baccala AA; Goemann MA; Clift SM; Ando DG; Levitsky HI; Cohen LK; Sanda MG; Mulligan RC; Partin AW; Carter HB; Piantadosi S; Marshall FF; Nelson WG
    Cancer Res; 1999 Oct; 59(20):5160-8. PubMed ID: 10537292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Granulocyte-macrophage colony-stimulating factor-transduced allogeneic cancer cellular immunotherapy: the GVAX vaccine for prostate cancer.
    Simons JW; Sacks N
    Urol Oncol; 2006; 24(5):419-24. PubMed ID: 16962494
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biological principles and clinical development of prostate cancer gene therapy.
    Sanda MG
    Semin Urol Oncol; 1997 Feb; 15(1):43-55. PubMed ID: 9050139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prostate cancer gene therapy].
    Nasu Y; Kumon H
    Nihon Rinsho; 2005 Feb; 63(2):335-8. PubMed ID: 15714988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C; Sanda MG
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy of murine prostate cancer using whole tumor cells killed ex vivo by herpes simplex viral thymidine kinase/ganciclovir suicide gene therapy.
    Pandha H; Eaton J; Greenhalgh R; Soars D; Dalgleish A
    Cancer Gene Ther; 2005 Jun; 12(6):572-8. PubMed ID: 15803141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging concepts in GM-CSF gene-transduced tumor vaccines for human prostate cancer.
    Lim M; Simons JW
    Curr Opin Mol Ther; 1999 Feb; 1(1):64-71. PubMed ID: 11249686
    [No Abstract]   [Full Text] [Related]  

  • 10. Gene therapy for prostate cancer.
    Gdor Y; Timme TL; Miles BJ; Kadmon D; Thompson TC
    Expert Rev Anticancer Ther; 2002 Jun; 2(3):309-21. PubMed ID: 12113054
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naïve prostate cancer.
    Simons JW; Carducci MA; Mikhak B; Lim M; Biedrzycki B; Borellini F; Clift SM; Hege KM; Ando DG; Piantadosi S; Mulligan R; Nelson WG
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3394-401. PubMed ID: 16740763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhanced therapeutic efficacy of IL-12, but not GM-CSF, expressing oncolytic herpes simplex virus for transgenic mouse derived prostate cancers.
    Varghese S; Rabkin SD; Liu R; Nielsen PG; Ipe T; Martuza RL
    Cancer Gene Ther; 2006 Mar; 13(3):253-65. PubMed ID: 16179929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical application for gene therapy in prostate cancer].
    Gotoh A; Kamidono S; Chung LW
    Hinyokika Kiyo; 1997 Nov; 43(11):829-33. PubMed ID: 9436031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen.
    Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H
    Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy with GM-CSF, interleukin-4 and herpes simplex virus thymidine kinase shows strong antitumor effect on lung cancer.
    Park KH; Kim G; Jang SH; Kim CH; Kwon SY; Yoo CG; Kim YW; Kwon HC; Kim CM; Han SK; Shim YS; Lee CT
    Anticancer Res; 2003; 23(2B):1559-64. PubMed ID: 12828142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
    Xia D; Moyana T; Xiang J
    Cell Res; 2006 Mar; 16(3):241-59. PubMed ID: 16541123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current status of experimental therapeutics for prostate cancer.
    Moon C; Park JC; Chae YK; Yun JH; Kim S
    Cancer Lett; 2008 Aug; 266(2):116-34. PubMed ID: 18440696
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ex-vivo gene therapy using cytokine-transduced tumor vaccines: molecular and clinical pharmacology.
    Simons JW; Mikhak B
    Semin Oncol; 1998 Dec; 25(6):661-76. PubMed ID: 9865681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Induction of G250-targeted and T-cell-mediated antitumor activity against renal cell carcinoma using a chimeric fusion protein consisting of G250 and granulocyte/monocyte-colony stimulating factor.
    Tso CL; Zisman A; Pantuck A; Calilliw R; Hernandez JM; Paik S; Nguyen D; Gitlitz B; Shintaku PI; de Kernion J; Figlin R; Belldegrun A
    Cancer Res; 2001 Nov; 61(21):7925-33. PubMed ID: 11691814
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.